Ardian-backed Neopharmed Gentili completed the acquisition of MDM.

Ardian-backed Neopharmed Gentili, an Italian pharmaceutical company, completed the acquisition of MDM, a pharmaceutical company based in Monza active in the distribution of pharmaceuticals, nutraceuticals and medical devices for neurology and orthopedics. Financial terms were not disclosed. “It is a highly strategic transaction and I would like to thank the Trognoni Family and the Monico Family, whose collaboration was pivotal to the successful completion of this acquisition. Furthermore, I am very happy to have Mr. Antonio Maggi, CEO of MDM, within our team. Thanks to his skills and experience, he will positively contribute to the Group’s future development. This transaction confirms Neopharmed’s growth strategy aimed at positioning itself among the main Italian pharmaceutical players," Alessandro Del Bono, Neopharmed Shareholder, Chairman and CEO.